Nicox S.A. (EPA:ALCOX)
0.4080
-0.0020 (-0.49%)
Apr 2, 2026, 5:35 PM CET
Nicox Employees
Nicox had 5 employees as of June 30, 2025.
Employees
5
Change
n/a
Growth
n/a
Revenue / Employee
€663,164
Profits / Employee
€5,412,303
Market Cap
35.96M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2025 | 5 | - | - | 5 | 0 |
| Dec 31, 2022 | 28 | -6 | -17.65% | 28 | 0 |
| Dec 31, 2021 | 34 | -3 | -8.11% | 32 | 2 |
| Dec 31, 2020 | 37 | -5 | -11.90% | 34 | 3 |
| Dec 31, 2019 | 42 | 8 | 23.53% | 39 | 3 |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| genOway Société anonyme | 148 |
| Adocia | 77 |
| OSE Immunotherapeutics | 64 |
| Fermentalg | 63 |
| Valerio Therapeutics Société anonyme | 25 |
| Aelis Farma | 24 |
| Advicenne | 13 |
| GenSight Biologics | 13 |
Nicox News
- 1 year ago - Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights - GlobeNewsWire
- 1 year ago - Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results - GlobeNewsWire
- 1 year ago - Nicox Provides Second Quarter 2024 Update - GlobeNewsWire
- 2 years ago - Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results - GlobeNewsWire
- 2 years ago - Nicox Provides Fourth Quarter 2023 Financial and Business Highlights - GlobeNewsWire
- 2 years ago - Nicox Provides First Half 2023 and Third Quarter 2023 Financial Results and Updates Key Milestones - GlobeNewsWire
- 2 years ago - Nicox Provides Second Quarter 2023 Financial and Business Highlights - GlobeNewsWire
- 2 years ago - Nicox Presented NCX 470 Phase 3 Mont Blanc Adaptive Design Data and Additional Subset Analysis Showing Superiority over Latanoprost at the World Glaucoma Congress - GlobeNewsWire